Bioethics, Public Health and the Treatment-Enhancement Distinction

Authors

  • Miguel Hugo Kottow Universidad Central de Chile Universidad de Chile

DOI:

https://doi.org/10.14422/rib.i07.y2018.002

Keywords:

biotechnology, enhancement, neuroscience, inequity

Abstract

Enormous resources are being invested in genetics, neuroscience and nanotechnology in search vital processes that might provide effective treatment for genetic and severe degenerative disorders, but these goals are still distant. Institutional and military resources are being poured into biotechnological developments for behavioral intervention (antisocial and military) and cognitive and moral enhancement for persons with difficulties (attention deficit disorder) as well as for healthy individuals. Enhancement will increase health and empowerment inequities to the detriment of the disadvantaged. Marked inequality in Latin America calls for an urgent focus on the compromised values at play in biotechnological interventions that will be unavailable to those in need.

Downloads

Download data is not yet available.

Author Biography

Miguel Hugo Kottow, Universidad Central de Chile Universidad de Chile

Profesor titular U. de Chile y Universidad Central de Chile.

Académico-investigador del Centro de Bioética, Facultad de Ciencias de la Salud, Universidad Central de Chile.

Maestro de la bioética chilena.

References

Dublevic, V., & Racine, E. (2017). Moral enhancement meets normative and empirical reality: assessing the practical feasibility of moral enhancement neurotechnologies. Bioethics, 31(5), 338-348. DOI: https://doi.org/10.1111/bioe.12355

Eaton, M. L., & Illes, J. (2007). Commercializing cognitive neurotechnology – the ethical terrain. Nature Biotechnology, 25(4), 393-398. DOI: https://doi.org/10.1038/nbt0407-393

Elliot, C. (2005). Adventure! Comedy! Tragedy! Robots! How bioethicists learned to stop worrying and embrace their inner cyborgs. Journal of Bioethical Inquiry, 2(1), 18-23. DOI: https://doi.org/10.1007/BF02448811

Erler, A. (2017). The limits of treatment-enhancement distinction as a guide to public policy. Bioethics, (31), 608-615. DOI: https://doi.org/10.1111/bioe.12377

Farrah, M. J., & Wolpe, P. R. (2004) Monitoring and Manipulating Brain Function. Hastings Center Report, 34(3), 35-45. DOI: https://doi.org/10.2307/3528418

Garzón Díaz, F. A. (2011). La Neuroética, una nueva línea de investigación para la bioética. Revista latinoamericana de bioética, 20(1), 6-9. DOI: https://doi.org/10.18359/rlbi.1041. DOI:https://doi.org/10.18359/rlbi.990

Gordijn, B., & ten Have, H. (2017). Bioenhancement of morality. Medicine, Healthcare and Philosophy, (20), 289-290. DOI: https://doi.org/10.1007/s11019-017-9791-0

Hamdan, A. C. (2017). Neuroética: la institucionalización de la ética en neurociencia. Revista Bioética, 25(2), 276-81.

Harris, J. (2011). Moral enhancement and freedom. Bioethics, 25(3), 102-111. DOI: https://doi.org/10.1111/j.1467-8519.2010.01854.x

Hedgecoe, A. (2010). Bioethics and the Reinforcement of Socio-technical Source. Social Studies of Science, 40, 163-186. DOI: https://doi.org/10.1177/0306312709349781

Illes, J., Blakemore, C., Hansson, M., Hensch, T., Leshner, A., Maestre, G., Magistretti, P., Quirion, R., & Strata, P. (2005). International perspectives on engaging the public in euroethics. Nature Reviews/Neuroscience, (6), 977-982. DOI: https://doi.org/10.1038/nrn1808

Kottow, M. (2017). Bioética y realce moral biotécnico" Revista bioética CFM. En prensa.

LeFever, G. B., Dawson, K. V., & Morrow, A. L. (1999). The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. American Journal of Public Health, 89(9), 1359-64.DOI: https://doi.org/10.2105/AJPH.89.9.1359

Noble, K. G., & Farrah, M. J. (2013). Neurocognitive consequences of socioeconomic disparities: the intersection of cognitive neuroscience and public health. Developmental Science, 16(5), 639-640. DOI: https://doi.org/10.1111/desc.12076

Persson, I., & Savulescu, J. (2013). Getting moral enhancement right: the desirability of moral bioenhancement. Bioethics, 27(3), 124-131. DOI: https://doi.org/10.1111/j.1467-8519.2011.01907.x

Persson, I., & Savulescu, J. (2016) Moral hard-wiring and moral enhancement. Bioethics, 31(4), 286-295. DOI: https://doi.org/10.1111/bioe.12314

Rowland, A. S., Lesesne, C. A., & Abramowitz, A. J. (2002). The epidemiology of attention-deficit/hyperactivity disorder (ADHD): A public health view. Developmental Disabilities Research Reviews, (8), 162-170. DOI: https://doi.org/10.1002/mrdd.10036

Roskies, A. L. (2002). Neuroethics for the New Millenium. Neuron, 35(1), 21-23. DOI: https://doi.org/10.1016/S0896-6273(02)00763-8

Selgelid, M. J. (2007). An Argument against Arguments for Enhancement. Studies in Ethics, Law, and Technology, 1(1).

Tennison, M. N., & Moreno, J. D. (2012). Neuroscience, Ethics and National Security: The State of the Art. Plos-Biol, 10(3), e10011289. DOI: https://doi.org/10.1371/journal.pbio.1001289

Published

2018-06-06

How to Cite

Kottow, M. H. (2018). Bioethics, Public Health and the Treatment-Enhancement Distinction. Revista Iberoamericana De Bioética, (7), 1–13. https://doi.org/10.14422/rib.i07.y2018.002